Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex

被引:59
作者
Jerremalm, E [1 ]
Hedeland, M
Wallin, I
Bondesson, U
Ehrsson, H
机构
[1] Karolinska Hosp, Karolinska Pharm, SE-17176 Stockholm, Sweden
[2] Natl Vet Inst, Dept Chem, SE-75189 Uppsala, Sweden
[3] Uppsala Univ, Div Analyt Pharmaceut Chem, SE-75123 Uppsala, Sweden
[4] Karolinska Inst, Dept Oncol Pathol, SE-17176 Stockholm, Sweden
关键词
biotransformation; HT-29; Pt(dach)Cl-2;
D O I
10.1023/B:PHAM.0000026444.67883.83
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To study the degradation of oxaliplatin in chloride media and evaluate the cytotoxicity of oxaliplatin in normal and chloride-deficient medium. Methods. The products of the reaction of oxaliplatin with chloride were separated on a Hypercarb S column with a mobile phase containing 40% methanol in 0.05 M ammonia and subjected to electrospray ionization mass spectrometry. The cytotoxicity of oxaliplatin in normal and chloride-deficient medium was evaluated by 30-min incubations on human colon adenocarcinoma cells (HT-29). Results. We identified a new intermediate degradation product, the monochloro monooxalato complex ([Pt(dach)oxCl](-)) and the final product, the dichloro complex (Pt(dach)Cl-2), by liquid chromatography-mass spectrometry. [Pt(dach)oxCl](-) was found as the negative ion, M-, at m/z 431, and the positive ion, [M+2H](+), m/z 433. Pt(dach)Cl-2 was found as the negative ion, [M-H](-), m/z 377, and the positive ion, [M+NH4](+), m/z 396. The fast initial degradation of oxaliplatin can be coupled to the fast formation of [Pt(dach)oxCl](-). In the cytotoxic assay, the cell survival was not affected by the chloride levels. Conclusions. [Pt(dach)oxCl](-), a new transformation product of oxaliplatin, has been identified. Its in vitro cytotoxic effect does not appear to exceed that of oxaliplatin.
引用
收藏
页码:891 / 894
页数:4
相关论文
共 10 条
[1]  
Allain P, 2000, DRUG METAB DISPOS, V28, P1379
[2]   KINETICS OF THE REACTION OF CIS-PLATINUM COMPOUNDS WITH DNA INVITRO [J].
BUTOUR, JL ;
MAZARD, AM ;
MACQUET, JP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 133 (01) :347-353
[3]   Pharmacokinetics of oxaliplatin in humans [J].
Ehrsson, H ;
Wallin, I ;
Yachnin, J .
MEDICAL ONCOLOGY, 2002, 19 (04) :261-265
[4]   RING-OPENING REACTIONS OF THE ANTICANCER DRUG CARBOPLATIN - NMR CHARACTERIZATION OF CIS-[PT(NH3)2(CBDCA-O)(5'-GMP-N7)] IN SOLUTION [J].
FREY, U ;
RANFORD, JD ;
SADLER, PJ .
INORGANIC CHEMISTRY, 1993, 32 (08) :1333-1340
[5]  
Graham MA, 2000, CLIN CANCER RES, V6, P1205
[6]  
Luo FR, 1998, ONCOL RES, V10, P595
[7]   Oxaliplatin: A review of evolving concepts [J].
Mani, S ;
Graham, MA ;
Bregman, DB ;
Ivy, P ;
Chaney, SG .
CANCER INVESTIGATION, 2002, 20 (02) :246-263
[8]  
Shord SS, 2002, ANTICANCER RES, V22, P2301
[9]  
SIEBERT G, 1972, Subcellular Biochemistry, V1, P277
[10]   Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin [J].
Videhult, P ;
Yachnin, J ;
Jerremalm, E ;
Lewensohn, R ;
Ehrsson, H .
CANCER LETTERS, 2002, 180 (02) :191-194